Masaya Baba

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4937310/publications.pdf

Version: 2024-02-01

		126708	128067
62	3,977	33	60
papers	citations	h-index	g-index
(2	(2	(2)	2076
62	62	62	3976
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15552-15557.	3.3	427
2	Kidney-Targeted Birt-Hogg-Dube Gene Inactivation in a Mouse Model: Erk1/2 and Akt-mTOR Activation, Cell Hyperproliferation, and Polycystic Kidneys. Journal of the National Cancer Institute, 2008, 100, 140-154.	3.0	223
3	VHL Tumor Suppressor Gene Alterations Associated With Good Prognosis in Sporadic Clear-Cell Renal Carcinoma. Journal of the National Cancer Institute, 2002, 94, 1569-1575.	3.0	216
4	Homozygous loss of <i>BHD</i> causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18722-18727.	3.3	203
5	Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes and Cancer, 2002, 34, 58-68.	1.5	197
6	Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. Journal of Pathology, 2005, 205, 377-387.	2.1	166
7	Identification and characterization of a novel folliculin-interacting protein FNIP2. Gene, 2008, 415, 60-67.	1.0	163
8	The von Hippel-Lindau Tumor Suppressor Protein Mediates Ubiquitination of Activated Atypical Protein Kinase C. Journal of Biological Chemistry, 2001, 276, 43611-43617.	1.6	161
9	Inactivation of the FLCN Tumor Suppressor Gene Induces TFE3 Transcriptional Activity by Increasing Its Nuclear Localization. PLoS ONE, 2010, 5, e15793.	1.1	146
10	Acidic Extracellular pH Induces Matrix Metalloproteinase-9 Expression in Mouse Metastatic Melanoma Cells through the Phospholipase D-Mitogen-activated Protein Kinase Signaling. Journal of Biological Chemistry, 2005, 280, 10938-10944.	1.6	145
11	Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through Hypoxia-inducible factor. Oncogene, 2003, 22, 2728-2738.	2.6	97
12	Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Research, 2003, 63, 5320-8.	0.4	94
13	Inactivation of von Hippel-Lindau Gene Induces Constitutive Phosphorylation of MET Protein in Clear Cell Renal Carcinoma. Cancer Research, 2006, 66, 3699-3705.	0.4	89
14	Direct Interaction of the \hat{I}^2 -Domain of VHL Tumor Suppressor Protein with the Regulatory Domain of Atypical PKC Isotypes. Biochemical and Biophysical Research Communications, 1999, 263, 491-497.	1.0	86
15	Folliculin Controls Lung Alveolar Enlargement and Epithelial Cell Survival through E-Cadherin, LKB1, and AMPK. Cell Reports, 2014, 7, 412-423.	2.9	84
16	PTENMMAC1TEP1 mutations in human primary renalâ€cell carcinomas and renal carcinoma cell lines. International Journal of Cancer, 2001, 91, 219-224.	2.3	83
17	Chronic AMPK activation via loss of FLCN induces functional beige adipose tissue through PGC-1α/ERRα. Genes and Development, 2016, 30, 1034-1046.	2.7	83
18	Regulation of Mitochondrial Oxidative Metabolism by Tumor Suppressor FLCN. Journal of the National Cancer Institute, 2012, 104, 1750-1764.	3.0	82

#	Article	IF	CITATIONS
19	Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF- \hat{l}^2 signaling. Molecular Cancer, 2010, 9, 160.	7.9	81
20	Genetic, epidemiologic and clinicopathologic studies of Japanese Asian patients with Birt–Hogg–Dubé syndrome. Clinical Genetics, 2016, 90, 403-412.	1.0	80
21	Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1624-31.	3.3	74
22	The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development. Blood, 2012, 120, 1254-1261.	0.6	57
23	MicroRNAâ€204â€5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma. Cancer Science, 2019, 110, 1897-1908.	1.7	55
24	Induction of SPARC by VEGF in Human Vascular Endothelial Cells. Biochemical and Biophysical Research Communications, 2001, 287, 422-426.	1.0	54
25	Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation. Human Molecular Genetics, 2014, 23, 5706-5719.	1.4	54
26	SPARC expression in primary human renal cell carcinoma: Upregulation of SPARC in sarcomatoid renal carcinoma. Human Pathology, 2001, 32, 1064-1070.	1.1	50
27	Identification of intragenic deletions and duplication in the ⟨i⟩FLCN⟨/i⟩ gene in Birtâ€Hoggâ€Dubé syndrome. Genes Chromosomes and Cancer, 2011, 50, 466-477.	1.5	50
28	MAPK Upstream Kinase (MUK)-binding Inhibitory Protein, a Negative Regulator of MUK/Dual Leucine Zipper-bearing Kinase/Leucine Zipper Protein Kinase. Journal of Biological Chemistry, 2000, 275, 21247-21254.	1.6	46
29	Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth. Oncogene, 2001, 20, 2727-2736.	2.6	46
30	A threeâ€gene expression signature model to predict clinical outcome of clear cell renal carcinoma. International Journal of Cancer, 2008, 123, 1126-1132.	2.3	46
31	Birt–Hogg–Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome. International Journal of Urology, 2016, 23, 204-210.	0.5	46
32	Germ-line Mutation Analysis in Patients with von Hippel-Lindau Disease in Japan: An Extended Study of 77 Families. Japanese Journal of Cancer Research, 2000, 91, 204-212.	1.7	45
33	Identification and characterization of Birt–Hogg–Dubé associated renal carcinoma. Journal of Pathology, 2007, 211, 524-531.	2.1	45
34	TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease. Molecular Cancer Research, 2019, 17, 1613-1626.	1.5	35
35	Bilateral testicular tumors in androgen insensitivity syndrome. International Journal of Urology, 2000, 7, 390-392.	0.5	31
36	<i>RBM10</i> â€" <i>TFE3</i> renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in breakâ€apart fluorescence <i>inâ€situ</i> hybridisation: study of 10 cases and a literature review. Histopathology, 2019, 75, 254-265.	1.6	29

#	Article	IF	Citations
37	Transfer of the von Hippel-Lindau gene to neuronal progenitor cells in treatment for Parkinson's disease. Annals of Neurology, 2003, 54, 352-359.	2.8	28
38	Vascular defects and liver damage by the acute inactivation of the VHL gene during mouse embryogenesis. Laboratory Investigation, 2006, 86, 664-675.	1.7	25
39	Loss of <i>Folliculin</i> Disrupts Hematopoietic Stem Cell Quiescence and Homeostasis Resulting in Bone Marrow Failure. Stem Cells, 2016, 34, 1068-1082.	1.4	25
40	Von Hippel-Lindau tumor suppressor protein transforms human neuroblastoma cells into functional neuron-like cells. Cancer Research, 2002, 62, 7004-11.	0.4	22
41	Folliculin Regulates Osteoclastogenesis Through Metabolic Regulation. Journal of Bone and Mineral Research, 2018, 33, 1785-1798.	3.1	21
42	Detection of germline deletions using real-time quantitative polymerase chain reaction in Japanese patients with von Hippel-Lindau disease. Cancer Science, 2006, 97, 400-405.	1.7	19
43	Stimulation of Motility of Human Renal Cell Carcinoma by SPARC/Osteonectin/BM-40 Associated with Type IV Collagen. Invasion & Metastasis, 1998, 18, 105-114.	0.5	18
44	Establishment of bone marrow-derived M-CSF receptor-dependent self-renewing macrophages. Cell Death Discovery, 2020, 6, 63.	2.0	18
45	A FLCN-TFE3 Feedback Loop Prevents Excessive Glycogenesis and Phagocyte Activation by Regulating Lysosome Activity. Cell Reports, 2020, 30, 1823-1834.e5.	2.9	18
46	H255Y and K508R missense mutations in tumour suppressorfolliculin (FLCN)promote kidney cell proliferation. Human Molecular Genetics, 2016, 26, ddw392.	1.4	17
47	Blood and lymphatic systems are segregated by the FLCN tumor suppressor. Nature Communications, 2020, 11, 6314.	5.8	17
48	BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. Human Molecular Genetics, 2018, 27, 2712-2724.	1.4	14
49	Splice-site mutation causing partial retention of intron in the FLCN gene in Birt-Hogg-Dubé syndrome: a case report. BMC Medical Genomics, 2018, 11, 42.	0.7	10
50	Folliculin Interacting Protein 1 Maintains Metabolic Homeostasis during B Cell Development by Modulating AMPK, mTORC1, and TFE3. Journal of Immunology, 2019, 203, 2899-2908.	0.4	10
51	Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Oncology Reports, 2005, 13, 1033-41.	1.2	10
52	Dual functions of angiopoietin-like protein 2 signaling in tumor progression and anti-tumor immunity. Genes and Development, 2019, 33, 1641-1656.	2.7	9
53	Review of hereditary leiomyomatosis renal cell carcinoma with focus on clinical and pathobiological aspects of renal tumors. Polish Journal of Pathology, 2017, 68, 284-290.	0.1	5
54	FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland. Biochemical and Biophysical Research Communications, 2020, 522, 931-938.	1.0	5

#	Article	lF	CITATIONS
55	Seventh BHD international symposium: recent scientific and clinical advancement. Oncotarget, 2022, 13, 173-181.	0.8	4
56	Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers. IScience, 2022, 25, 104463.	1.9	4
57	Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide–chlorambucil conjugate. Cancer Science, 2022, 113, 2352-2367.	1.7	3
58	Establishment and characterization of BHD-F59RSVT, an immortalized cell line derived from a renal cell carcinoma in a patient with Birt–Hogg–Dubé syndrome. Laboratory Investigation, 2017, 97, 343-351.	1.7	2
59	Editorial Comment to AnnexinÂA1 expression is correlated with malignant potential of renal cell carcinoma. International Journal of Urology, 2019, 26, 291-291.	0.5	1
60	t(6; 11) renal cell carcinoma. A case report successfully diagnosed by using fluorescence in situ hybridization. IJU Case Reports, 2021, 4, 375-378.	0.1	1
61	Hereditary Renal Cell Carcinoma. , 2017, , 19-82.		1
62	Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Oncology Reports, 0, , .	1.2	1